

Bafisontamab

Cat. No.:	HY-P99455
CAS No.:	2437210-79-0
Target:	EGFR; c-Met/HGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity ^[1] .	
IC ₅₀ & Target	EGFR	c-Met
In Vivo	Bafisontamab (EMB-01) induces significantly stronger anti-tumor activity in PDX and CDX tumor models than that of anti-EGFR mAb or anti-cMet mAb alone. Bafisontamab shows significant anti-tumor activity in anti-EGFR mAb resistant tumor model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Ren F, et al. EMB-01: An innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy. Cancer Research, 2020, 80(16_Supplement): 528-528.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA